Brief: Quanterix Announces Landmark Nature Study Redefining Alzheimer’S Disease Neuropathology Prevalence
22/12/2025 12:45
Dec 22 (Reuters) - Quanterix Corp QTRX.O: QUANTERIX ANNOUNCES LANDMARK NATURE STUDY REDEFINING ALZHEIMER’S DISEASE NEUROPATHOLOGY PREVALENCE Source text: ID:nBw82TG8qa Further company coverage: QTRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Quanterix
See all newsBrief: Alzpath And Quanterix Expand Strategic Licensing Agreement To Advance Next Generation Alzheimer's Disease Biomarker Research
Quanterix Corporation reports results for the quarter ended June 30 - Earnings Summary
Quanterix Q2 revenue rises 34% but cuts 2026 outlook
Quanterix Corporation expected to post a loss of 46 cents a share - Earnings Preview
Quanterix Corp expected to post a loss of 46 cents a share - Earnings Preview